These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 28558972

  • 1. Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer.
    McGee TD, Yi HA, Allen WJ, Jacobs A, Rizzo RC.
    Bioorg Med Chem Lett; 2017 Jul 15; 27(14):3177-3184. PubMed ID: 28558972
    [Abstract] [Full Text] [Related]

  • 2. Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation.
    Allen WJ, Yi HA, Gochin M, Jacobs A, Rizzo RC.
    Bioorg Med Chem Lett; 2015 Jul 15; 25(14):2853-9. PubMed ID: 26013847
    [Abstract] [Full Text] [Related]

  • 3. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S, Zhu Y, Ye S, Qi Q, Xia S, Ma Z, Yu F, Wang Q, Zhang R, Jiang S, Lu L.
    J Virol; 2017 Jan 01; 91(1):. PubMed ID: 27795416
    [Abstract] [Full Text] [Related]

  • 4. Footprint-based identification of viral entry inhibitors targeting HIVgp41.
    Holden PM, Kaur H, Goyal R, Gochin M, Rizzo RC.
    Bioorg Med Chem Lett; 2012 Apr 15; 22(8):3011-6. PubMed ID: 22425565
    [Abstract] [Full Text] [Related]

  • 5. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S, Zhao Q, Debnath AK.
    Curr Pharm Des; 2002 Apr 15; 8(8):563-80. PubMed ID: 11945159
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L, Tong P, Yu X, Pan C, Zou P, Chen YH, Jiang S.
    Biochim Biophys Acta; 2012 Dec 15; 1818(12):2950-7. PubMed ID: 22867851
    [Abstract] [Full Text] [Related]

  • 7. Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
    Cai L, Gochin M, Liu K.
    Curr Top Med Chem; 2011 Dec 15; 11(24):2959-84. PubMed ID: 22044229
    [Abstract] [Full Text] [Related]

  • 8. Strategies for lead discovery: application of footprint similarity targeting HIVgp41.
    Holden PM, Allen WJ, Gochin M, Rizzo RC.
    Bioorg Med Chem; 2014 Jan 01; 22(1):651-61. PubMed ID: 24315195
    [Abstract] [Full Text] [Related]

  • 9. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
    Chao L, Lu L, Yang H, Zhu Y, Li Y, Wang Q, Yu X, Jiang S, Chen YH.
    PLoS One; 2013 Jan 01; 8(5):e66156. PubMed ID: 23741527
    [Abstract] [Full Text] [Related]

  • 10. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 11. An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
    Liu Y, Ke Z, Wu KY, Liu S, Chen WH, Jiang S, Jiang ZH.
    ChemMedChem; 2011 Sep 05; 6(9):1654-64. PubMed ID: 21688394
    [Abstract] [Full Text] [Related]

  • 12. ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer.
    Yu F, Lu L, Liu Q, Yu X, Wang L, He E, Zou P, Du L, Sanders RW, Liu S, Jiang S.
    Biochim Biophys Acta; 2014 May 05; 1838(5):1296-305. PubMed ID: 24388952
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
    Ma X, Tan J, Su M, Li C, Zhang X, Wang C.
    PLoS One; 2014 May 05; 9(11):e111923. PubMed ID: 25393106
    [Abstract] [Full Text] [Related]

  • 16. Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
    He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q.
    J Virol; 2008 Jul 05; 82(13):6349-58. PubMed ID: 18417584
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652.
    Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S, He Y.
    J Biol Chem; 2012 Jun 08; 287(24):20281-9. PubMed ID: 22511760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.